Complex disease models can provide more predictive target validation data by better reflecting disease biology and improving translational relevance. The challenge is to balance biological complexity with model robustness, usability, and reproducibility.
Evotec combines disease-relevant in vitro models with tailored target perturbation strategies and validated readouts to generate high-confidence data for target de-risking and prioritization. Our experts help select the right model, perturbation approach, and readout strategy to support confident target selection and progression.
At Evotec
>50
Successful target validation projects using complex cellular and disease models
>100
Complex disease models enabled for target validation
>200
Assay readouts validated across complex in vitro disease models
>50
Successful target validation projects using complex cellular and disease models
>100
Complex disease models enabled for target validation
>200
Assay readouts validated across complex in vitro disease models
Evotec Expertise in Target Validation Using Complex Disease Models
Evotec provides end-to-end target validation support, from strategy and model selection to experimental execution and delivery of decision-ready data. Our 3R approach identifies the right model, perturbation technology, and readout for each project.
- Target validation in complex disease models: Experience across primary and iPSC-derived cells, co-cultures, and 2D/3D models. Disease-relevant genotypes can be introduced via gene editing, and new or partner models can be onboarded efficiently.
- Broad target perturbation toolbox: Diverse genetic perturbation and delivery technologies adapted to various cellular states. Experts select optimal strategies to generate causal, disease-relevant data.
- Validated, disease-relevant readouts: Established readouts assess perturbation efficiency and functional effects on disease phenotypes, tailored to model, target, and project goals.
- Accelerated in vitro to in vivo translation: Strategies are designed with the full drug discovery continuum in mind. AAV-based delivery can support translation from in vitro proof-of-concept to in vivo validation and reduce risk.
What Differentiates Evotec’s Complex Disease Model Target Validation Platform
At Evotec, target validation spans the drug discovery continuum, guiding decisions from early discovery through hit finding, mechanism-of-action studies, and biomarker selection. By combining scientific expertise, complex disease models, and integrated capabilities, we strengthen target confidence, reduce risk, and support clinical progression.
Figure 1: Overview of Evotec’s 3R framework for target validation in complex disease models, integrating the right model, perturbation technology, and readout strategy to generate disease-relevant insights and support confident drug discovery decisions.
